drugset / Trial / NCT00529360
Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL
Non-randomizedSingle-groupOpen-labelTreatment
Summary
Hypothesis: Myeloablative conditioning using a dose escalation of clofarabine in combination with cytarabine (ARA-C) and total body irradiation (TBI) will lead to improved survival for previously untransplanted children and adolescents with acute lymphoblastic leukemia (ALL) and acute non-lymphoblastic leukemia (ANLL)followed by allogeneic stem cell transplantation (AlloSCT).
Timeline
- Start
- 2007-06
- Primary completion
- 2016-01
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clofarabine | Other / unclassified | 30 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 40 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 46 mg/m2 | Intravenous |
| Subject | Clofarabine | Other / unclassified | 52 mg/m2 | Intravenous |